Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis

Purpose: Tamoxifen is a drug used for hormone receptor-positive breast cancers, primarily metabolised by the CYP2D6 enzyme into active metabolites such as endoxifen. CYP2D6 displays varying degrees of activity depending on its genotype. This study aims to analyse the effect of an early increase in t...

Full description

Bibliographic Details
Main Authors: Isabel Blancas, Marina Linares-Rodríguez, Eduardo Martínez de Dueñas, Carmen Herrero-Vicent, María D. Molero-Mir, José M. Garrido, Fernando Rodríguez-Serrano
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Breast
Subjects:
Breast cancer
Tamoxifen
CYP2D6
Disease-free survival
Overall survival
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977623004290

Internet

http://www.sciencedirect.com/science/article/pii/S0960977623004290

Similar Items